View the latest news on recent AbbVie and FutureGen deal and two recent interviews conducted by PharmaDJ with AbbVie BD executives (in Chinese):
AbbVie & FutureGen Deal
自免一哥”为何扩增中国公司人员 ?
对中国兴趣不减，艾伯维继续扩展五大领域合作
At AbbVie, we partner to achieve two important outcomes: deliver innovative medicines and make a remarkable impact on people’s lives.
AbbVie’s Partnering Day provides an opportunity to:
Meet with our senior research and partnership leadership teams from AbbVie External Innovations and R&D to discuss your ideas and research in a one-on-one setting
Learn about our strategy, therapeutic areas of interest, and approach(es) to partnering
Share information about your company, pipeline, and discovery platforms with members of the AbbVie R&D organization and AbbVie External Innovations.
*There is no fee to register for this event and/or participate in 1:1 meetings. You may register to attend only the General Session presentations. 1:1 meetings must be approved/confirmed.
All applications for 1:1 meetings must include non-confidential supporting materials such as slide decks, poster presentations, and/or research papers in English.
AbbVie Asia Capabilities:
Headquarters situated within most Asian countries and regions including but not limited to China, Japan, S. Korea, Singapore, etc. with full supporting commercial, regulatory, and medical affairs teams
Global manufacturing facility in Singapore
Experienced in Asia cross-border deals
For more information on AbbVie’s partnering approach, please visit: AbbVie Partnering Site
AbbVie is seeking to explore exciting new cross-border licensing opportunities with innovative biotechs in Asia. In addition to attending the General Session presentations, Asian academics, VC, Biotechs are also welcome to apply for 1:1 meetings with AbbVie senior executives. 1:1 meetings will take place immediately after the General Session.
Selection Criteria for 1:1 Partnering
• Companies must have applied for a 1:1 meeting in advance and have been approved
• Project proposals will be evaluated based on project stage, strategic fit (i.e., AbbVie’s five areas of therapeutic
interest), and differentiation
Wednesday, September 18, 2024
General Session
08:30 – 09:30 Registration & Light Breakfast
09:30 – 10:30 Overview of AbbVie’s Corporate Strategy and AbbVie’s External Innovation Strategy
- Strategic interests from the S&E perspective
- AbbVie Ventures investment strategy
- AbbVie China strategy and commercial capabilities
- “Best practices in partnering” panel with AbbVie partners
- Q&A
10:30 – 11:00 Networking Break
11:00 – 17:00 1:1 Partnering Meetings
*all times are Local Shanghai Time
Questions? Please email
chris.zhu@abbvie.com
For additional information on AbbVie’s partnering approach, please click here.
Where/when is the event taking place?
The event will take place in-person at the St. Regis Jing An Hotel in Shanghai on September 18, 2024. For more information on the venue, please click here.
Is there a registration or application fee involved?
There is no fee to register for this event and/or participate in 1:1 meetings. We encourage all potential interested parties within the Asian Pacific life science ecosystem (i.e., biotechs, healthcare VCs, academics) to attend/apply. Due to limited space, vendors and service providers are not eligible to register.
May I attend the event onsite in Shanghai without applying for 1:1 Partnering?
Yes. If you are from a biopharmaceutical company, VC or hospital/academia, you are invited to attend to listen to the General Session presentations and for general networking. Vendors/service providers are not able eligible to join. To register to attend the event, please visit here.
Should I submit supporting documents with my application?
If you are interested in applying for a 1:1 meeting, yes. Please click here to submit. If you are only attending the General Session, you do not need to submit supporting documents. Please be sure to attach non-confidential supporting materials such as slide decks, poster presentations and/or research papers as part of your application.
Please do not submit any confidential information as any submitted information be treated as non-confidential. Of course, we will use this information only internally for evaluation purposes and will not further distribute.
What types of cross border deals are of interest to AbbVie?
Depending on the asset and stage of development, AbbVie is flexible and experienced in terms of potential deal structure types (i.e., in-licensing, co-development, co-commercial, etc.).
Where can I find more information about AbbVie and its approach to partnering?
Please click here to visit the AbbVie Partnering Site.